[Pharmacogenetic markers of metabolic disorders in the treatment with valproic acid].

[Pharmacogenetic markers of metabolic disorders in the treatment with valproic acid].

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(10. Vyp. 2):82-89

Authors: Drokov AP, Lipatova LV, Shnayder NA, Nasyrova RF

Abstract
The review includes studies on the association between the use of VA drugs and weight gain in patients with epilepsy as well as other valproate-induced adverse drug reactions, including insulin resistance. Understanding the mechanisms of significant weight gain of patients taking VA drugs will help personalize antiepileptic therapy and minimize the risk of valproate-induced obesity.

PMID: 30698550 [PubMed - in process]

from A via a.sfakia on Inoreader http://bit.ly/2GcY5oD